# Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

> **NCT02493517** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 128 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Lanreotide Autogel®
- **DRUG:** Lanreotide Acetate

## Key facts

- **NCT ID:** NCT02493517
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-11
- **Final completion:** 2017-02-16
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2019-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493517, "Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02493517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*